Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $175.33

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $175.33.

Several analysts have recently issued reports on the company. TD Cowen decreased their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and set a $163.00 price target (down from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $120.72 on Monday. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market cap of $7.30 billion, a price-to-earnings ratio of 17.00, a PEG ratio of 1.04 and a beta of 0.57. The company’s 50 day moving average is $116.81 and its two-hundred day moving average is $111.91.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,753 shares of company stock valued at $816,289. 4.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Swedbank AB purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter worth about $106,936,000. Rubric Capital Management LP acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $65,812,000. Pacer Advisors Inc. raised its stake in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after purchasing an additional 527,187 shares during the period. Baupost Group LLC MA lifted its position in shares of Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after purchasing an additional 440,552 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock valued at $48,122,000 after purchasing an additional 427,246 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.